NCT01302847: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01302847 |
|---|---|
| Title | Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 20, 2011 |
| Completion date | Jan. 20, 2021 |
| Required reporting date | Jan. 20, 2022, midnight |
| Actual reporting date | Jan. 11, 2022 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |